- Email: [email protected]
CME examination
To claim CME credit, complete this case-based posttest online at http://www.aad.org/JAAD/. Note: CME quizzes are available after the first of the month in which the article is published. A minimum score of 70% must be achieved to claim CME credit. If you have any questions, please contact the Member Resource Center of the American Academy of Dermatology at toll-free (866) 503-SKIN (7546), (847) 240-1280 (for international members), or by e-mailing [email protected].
CME examination Identification No. JB0215 February 2015 issue of the Journal of the American Academy of Dermatology.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. J Am Acad Dermatol 2015;72:221-36.
Directions for questions 1 and 2: Choose the single best response. A 64-year-old woman with BRAF V600E mutated metastatic melanoma was being considered for treatment with vemurafenib (a BRAF inhibitor) or trametinib (a MEK inhibitor). She had a history of many atypical nevi and nonmelanoma skin cancers. You conducted a skin examination and counseled the patient regarding potential skin toxicities associated with these targeted therapies. 1. The constellation of cutaneous toxicities associated with MEK inhibitors most closely resembles those of what other family of targeted therapies? a. Mammalian target of rapamycin inhibitors b. RAF inhibitors c. Antiangiogenesis inhibitors d. Epidermal growth factor receptor inhibitors e. Hedgehog signaling pathway inhibitors
You made the patient aware of the propensity for dynamic changes within nevi and the development of second primary melanomas and squamous cell carcinoma while undergoing therapy with BRAF inhibitors. 2. What frequency of visits to your office would be prudent if the patient began vemurafenib therapy? a. Baseline, then every 2 months until treatment ends b. Baseline, then every month for 6 months, then every 8 weeks c. Baseline, then every 3 to 6 months d. On an as-needed basis e. None of the above
237
CME examination Identification No. JB0215 February 2015 issue of the Journal of the American Academy of Dermatology.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. J Am Acad Dermatol 2015;72:221-36.
Directions for questions 1 and 2: Choose the single best response. A 64-year-old woman with BRAF V600E mutated metastatic melanoma was being considered for treatment with vemurafenib (a BRAF inhibitor) or trametinib (a MEK inhibitor). She had a history of many atypical nevi and nonmelanoma skin cancers. You conducted a skin examination and counseled the patient regarding potential skin toxicities associated with these targeted therapies. 1. The constellation of cutaneous toxicities associated with MEK inhibitors most closely resembles those of what other family of targeted therapies? a. Mammalian target of rapamycin inhibitors b. RAF inhibitors c. Antiangiogenesis inhibitors d. Epidermal growth factor receptor inhibitors e. Hedgehog signaling pathway inhibitors
You made the patient aware of the propensity for dynamic changes within nevi and the development of second primary melanomas and squamous cell carcinoma while undergoing therapy with BRAF inhibitors. 2. What frequency of visits to your office would be prudent if the patient began vemurafenib therapy? a. Baseline, then every 2 months until treatment ends b. Baseline, then every month for 6 months, then every 8 weeks c. Baseline, then every 3 to 6 months d. On an as-needed basis e. None of the above
237